MedTrace Logo

Vitamin D Metabolism in Chronic Kidney Disease Patients

NCT01528176 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2012-02-14

No results posted yet for this study

Summary

To determine whether or not chronic kidney disease (CKD), stages III-V and ESRD , is associated with altered vitamin D metabolism related to fibroblast growth factor-23 (FGF-23) stimulation of Cyp24 and whether they have resistance to elevations of 25 Hydroxyvitamin D (25(OH)D3) after cholecalciferol supplementation.

To determine if such resistance is related to enhanced catabolism of (25(OH)related to elevated levels of FGF-23.

Conditions

  • Vitamin D Metabolism is in Chronic Kidney Disease

Interventions

DRUG

10,000 IU of cholecalciferol for a total of 8 weeks

Subjects were treated with weekly oral administration of 10,000 IU of cholecalciferol for a total of 8 weeks in order to correct the vitamin D deficiency.

Sponsors & Collaborators

  • Memphis VA Medical Center

    lead FED

Principal Investigators

  • Barry M Wall, MD · Memphis , TN ,VAMC

  • HALA M Alshayeb, MD · UTHSC, UCH

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01528176 on ClinicalTrials.gov